270 related articles for article (PubMed ID: 34139069)
1. Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case.
Atak MF; Farabi B; Akbayrak A; Kalelioğlu MB; Rao BK
J Cosmet Dermatol; 2021 Aug; 20(8):2387-2389. PubMed ID: 34139069
[No Abstract] [Full Text] [Related]
2. AGEP sine pustulosis induced by hydroxychloroquine used for COVID-19 infection.
Demircioğlu D; Karabıyık N; Durmaz EÖ; Demirkesen C; Şahin S
Dermatol Ther; 2022 Mar; 35(3):e15263. PubMed ID: 34907646
[No Abstract] [Full Text] [Related]
3. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19).
Robustelli Test E; Vezzoli P; Carugno A; Raponi F; Gianatti A; Rongioletti F; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e457-e459. PubMed ID: 32386448
[No Abstract] [Full Text] [Related]
4. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD;
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093
[No Abstract] [Full Text] [Related]
5. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
6. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Litaiem N; Hajlaoui K; Karray M; Slouma M; Zeglaoui F
Dermatol Ther; 2020 Jul; 33(4):e13565. PubMed ID: 32401410
[No Abstract] [Full Text] [Related]
7. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis.
Pearson KC; Morrell DS; Runge SR; Jolly P
Cutis; 2016 Mar; 97(3):212-6. PubMed ID: 27023083
[TBL] [Abstract][Full Text] [Related]
8. Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia.
Pezzarossa E; Ungari M; Caresana G; Sagradi F; Cimardi L; Pan A; Testa S; Aguggini S; Varotti E; Tanzi G; Manotti L; Ferrero G; Gusolfino MD; Trombatore M;
Am J Dermatopathol; 2021 May; 43(5):342-348. PubMed ID: 33405402
[TBL] [Abstract][Full Text] [Related]
9. The First Pediatric Case of Acute Generalized Exanthematous Pustulosis Caused by Hydroxychloroquine.
Liccioli G; Marrani E; Giani T; Simonini G; Barni S; Mori F
Pharmacology; 2019; 104(1-2):57-59. PubMed ID: 31067554
[TBL] [Abstract][Full Text] [Related]
10. Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine.
Haraszti S; Sendil S; Jensen N
Am J Case Rep; 2020 Oct; 21():e926901. PubMed ID: 33097683
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing.
Charfi O; Kastalli S; Sahnoun R; Lakhoua G
Indian J Pharmacol; 2015; 47(6):693-4. PubMed ID: 26729969
[TBL] [Abstract][Full Text] [Related]
12. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
Enos T; Jeong HS; Vandergriff T; Jacobe HT; Chong BF
Dermatol Ther; 2020 Nov; 33(6):e13834. PubMed ID: 32542893
[No Abstract] [Full Text] [Related]
13. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature.
Bailey K; McKee D; Wismer J; Shear N
J Cutan Med Surg; 2013; 17(6):414-8. PubMed ID: 24138979
[TBL] [Abstract][Full Text] [Related]
14. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.
Nili A; Zarei E; Ghamari A; Farid AS; Tavakolpour S; Daneshpazhooh M; Mahmoudi H
Int Immunopharmacol; 2020 Dec; 89(Pt B):107093. PubMed ID: 33091817
[TBL] [Abstract][Full Text] [Related]
15. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation.
Duman H; Topal IO; Kocaturk E; Cure K; Mansuroglu I
An Bras Dermatol; 2017; 92(3):404-406. PubMed ID: 29186260
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine.
Castner NB; Harris JC; Motaparthi K
Dermatol Ther; 2018 Sep; 31(5):e12660. PubMed ID: 30152569
[TBL] [Abstract][Full Text] [Related]
17. An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
Daye M; Oltulu P
J Cosmet Dermatol; 2022 Jan; 21(1):13-15. PubMed ID: 34826196
[No Abstract] [Full Text] [Related]
18. Acute generalized exanthematous pustulosis induced by generic hydroxychloroquine.
Wang G; Zhuo N; Li J
J Cosmet Dermatol; 2022 Aug; 21(8):3608-3610. PubMed ID: 34757679
[No Abstract] [Full Text] [Related]
19. Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test.
Stingeni L; Francisci D; Bianchi L; Hansel K; Tramontana M; Di Candilo F; Mannarino MR; Pirro M
Contact Dermatitis; 2021 Sep; 85(3):366-368. PubMed ID: 33834491
[No Abstract] [Full Text] [Related]
20. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Schwartz RA; Janniger CK
Dermatol Ther; 2020 May; 33(3):e13380. PubMed ID: 32253799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
